Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of dexpramipexole in amyotrophic lateral sclerosis
NL-OMON37292Phase 3Withdrawn
- Sponsor
- Biogen
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dexpramipexole in amyotrophic lateral sclerosis (ALS), sponsored by Biogen. Primary endpoints: Incidence of adverse events and serious adverse events, Discontinuation due to adverse event and 2 more. Planned start Sep 2012; status: withdrawn.
02
Drugs
dexpramipexole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON37292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37292.